US 12,295,944 B2
Methods of treating gastrointestinal stromal tumors
Rodrigo Ruiz Soto, Waltham, MA (US); Oliver Rosen, Waltham, MA (US); and Jama Pitman, Waltham, MA (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Jun. 21, 2024, as Appl. No. 18/750,014.
Application 18/750,014 is a division of application No. 18/500,792, filed on Nov. 2, 2023, granted, now 12,059,411.
Application 18/500,792 is a division of application No. 18/091,743, filed on Dec. 30, 2022, granted, now 11,813,251, issued on Nov. 14, 2023.
Application 17/180,218 is a division of application No. 17/028,640, filed on Sep. 22, 2020, granted, now 10,966,966, issued on Apr. 6, 2021.
Application 18/091,743 is a continuation of application No. 17/735,682, filed on May 3, 2022, granted, now 11,576,904, issued on Feb. 14, 2023.
Application 17/735,682 is a continuation of application No. 17/727,307, filed on Apr. 22, 2022, granted, now 11,534,432, issued on Dec. 27, 2022.
Application 17/727,307 is a continuation of application No. 17/583,985, filed on Jan. 25, 2022, granted, now 11,344,536, issued on May 31, 2022.
Application 17/583,985 is a continuation of application No. 17/180,218, filed on Feb. 19, 2021, granted, now 11,266,635, issued on Mar. 8, 2022.
Application 17/028,640 is a continuation of application No. PCT/US2020/045876, filed on Aug. 12, 2020.
Claims priority of provisional application 63/023,921, filed on May 13, 2020.
Claims priority of provisional application 63/023,936, filed on May 13, 2020.
Claims priority of provisional application 62/968,927, filed on Jan. 31, 2020.
Claims priority of provisional application 62/968,945, filed on Jan. 31, 2020.
Claims priority of provisional application 62/936,018, filed on Nov. 15, 2019.
Claims priority of provisional application 62/926,281, filed on Oct. 25, 2019.
Claims priority of provisional application 62/904,198, filed on Sep. 23, 2019.
Claims priority of provisional application 62/885,797, filed on Aug. 12, 2019.
Prior Publication US 2024/0342144 A1, Oct. 17, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4745 (2006.01); A61P 9/12 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 31/4745 (2013.01); A61P 9/12 (2018.01); A61P 35/00 (2018.01)] 1 Claim
 
1. A method of treating a patient suffering from Grade 3 arthralgia while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 arthralgia, then administering to the patient 100 mg daily ripretinib for at least 28 days.